- Evaluation of serum Brain-derived Neurotrophic Factor, IL-6, IL-10, and TNF-α Cognitive Function, and Sleep Quality in Elderly Patients with Major Depressive Disorder and Somatic Symptoms:

Ya Gao

doi:10.5937/jomb0-53387

Ya Gao The Third Central Hospital of Tianjin

DOI: https://doi.org/10.5937/jomb0-53387

Keywords: MDD in the elderly; serum Brain-derived Neurotrophic Factor, IL-6, IL-10, and TNF-α Cognitive Function, somatization symptoms;

Abstract

Objective: it aimed to analyze the relationship between somatization in elderly patients with major depressive disorder (MDD) and brain-derived neurotrophic factor (BDNF), IL-6, IL-10, and TNF-α cognitive function, and sleep quality(SQ).

Method: 80 elderly patients with MDD were grouped based on the somatic self-rating scale (SSS): the subjects with somatic symptoms (SS) as the AG and the subjects without SS as the BG. Additionally, 25 healthy volunteers from the same period were included as the control group (CG). SQ scores, BDNF and its precursor (ProBDNF), and cognitive function scores of the subjects were collected.

Result: the SQ and SS scores of AG and BG were visibly higher as against CG, and those of AG were visibly higher in contrast to BG; The cognitive function scores of AG and BG were visibly lower as against CG, and the score of AG was visibly lower in contrast to BG (P <0.05). There was similar in BDNF and ProBDNF levels between AG and BG (P >0.05). CRP, IL-6, IL-10, and TNF-α in both AG and BG were visibly higher as against CG; Those were visibly higher in AG as against BG (P <0.05).The SS scores of the patients suggested a visible negative correlation with cognitive function scores and a highly visible positive correlation with SQ scores.

Conclusion: somatization symptoms may affect the SQ and cognitive function of people with depression, leading to an exacerbation of inflammatory responses; BDNF and ProBDNF levels may be more influenced by the overall state of depression rather than being determined solely by SS.

References

1. Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine, 2022;387(18):1637-1648.
2. Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. The Lancet, 2023;401(10371):141-153.
3. Hsieh MH. Electroconvulsive therapy for treatment-resistant depression. Prog Brain Res. 2023;281:69-90.
4. Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion on Drug Safety, 2022;21(6):777-787.
5. Li Y, Liu H. Clinical powers of aminoacyl tRNA synthetase complex interacting multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma. Cancer Biomarkers: Section A of Disease Markers, 2022;34(3):359-374.
6. Zheng CM, Piao XM, Byun YJ, Song SJ, Kim SK, Moon SK, Choi YH, Kang HW, Kim WT, Kim YJ, Lee SC, Kim WJ, Yun SJ. Study on the use of nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues. Cancer Genetics, 2022;268-269:137-143.
7. Jin Z, Zhang W, Liu H, Ding A, Lin Y, Wu SX, Lin J. Potential therapeutic application of local anesthetics in cancer treatment. Recent Patents on Anti-Cancer Drug Discovery, 2022;17(4):326-342.
8. Frank P, Batty GD, Pentti J, Jokela M, Poole L, Ervasti J, Vahtera J, Lewis G, Steptoe A, Kivimäki M. Association between depression and physical conditions requiring hospitalization. JAMA Psychiatry, 2023;80(7):690-699.
9. Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E. The association of hypogonadism with depression and its treatments. Frontiers in Endocrinology, 2023;14:1198437(1-14).
10. Steffens DC. Treatment-resistant depression in older adults. The New England Journal of Medicine, 2024;390(7):630-639.
11. Lorenzo EC, Kuchel GA, Kuo CL, Moffitt TE, Diniz BS. Major depression and the biological hallmarks of aging. Ageing Research Reviews, 2023;83:101805(1-27).
12. Mirchandaney R, Barete R, Asarnow LD. Moderators of cognitive behavioral treatment for insomnia on depression and anxiety outcomes. Current Psychiatry Reports, 2022;24(2):121-128.
13. Heissel A, Heinen D, Brokmeier LL, Skarabis N, Kangas M, Vancampfort D, Stubbs B, Firth J, Ward PB, Rosenbaum S, Hallgren M, Schuch F. Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. British Journal of Sports Medicine 57(Pt A):bjsports-2022-106282, 2023;57(16):1049-1057.
14. Kofod J, Elfving B, Nielsen EH, Mors O, Köhler-Forsberg O. Depression and inflammation: correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. European Neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2022;54:116-125.
15. Runia N, Yücel DE, Lok A, de Jong K, Denys DAJP, van Wingen GA, Bergfeld IO. The neurobiology of treatment-resistant depression: A systematic review of neuroimaging studies. Neuroscience and Biobehavioral Reviews, 2022;132:433-448.
16. Hagatulah N, Bränn E, Oberg AS, Valdimarsdóttir UA, Shen Q, Lu D. Perinatal depression and risk of mortality: nationwide, register based study in Sweden. BMJ, 2024;384:e075462(1-10).
17. Vita G, Compri B, Matcham F, Barbui C, Ostuzzi G. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2023 Mar 31;3(3):CD011006(1-80).
18. Mitra A, Raichle ME, Geoly AD, Kratter IH, Williams NR. Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression. Proceedings of the National Academy of Sciences of the United States of America, 2023;120(21):e2218958120(1-6).
19. Siddiqi SH, Kandala S, Hacker CD, Bouchard H, Leuthardt EC, Corbetta M, Morey RA, Brody DL. Precision functional MRI mapping reveals distinct connectivity patterns for depression associated with traumatic brain injury. Science Translational Medicine, 2023;15(703):eabn0441(1-11).
20. Maruani J, Boiret C, Leseur J, Romier A, Bazin B, Stern E, Lejoyeux M, Geoffroy PA. Major depressive episode with insomnia and excessive daytime sleepiness: a more homogeneous and severe subtype of depression. Psychiatry Research, 2023;330:115603(1-8).
21. Currie JM, Mercer M, Michael R, Pichardo D. New caregiver diagnoses of severe depression and child asthma controller medication adherence. International Journal of Environmental Research and Public Health, 2023;20(11):5986(1-10).
22. Zwolińska W, Skibinska M, Słopień A, Dmitrzak-Węglarz M. ProBDNF as an indicator of improvement among women with depressive episodes. Metabolites, 2022;12(4):358(1-9).
23. Sochal M, Ditmer M, Binienda A, Gabryelska A, Białasiewicz P, Talar-Wojnarowska R, Fichna J, Małecka-Wojciesko E. Relation between selected sleep parameters, depression, anti-tumor necrosis factor therapy, and the brain-derived neurotrophic factor pathway in inflammatory bowel disease. Metabolites, 2023;13(3):450(1-18).
24. Min X, Wang G, Cui Y, Meng P, Hu X, Liu S, Wang Y. Association between inflammatory cytokines and symptoms of major depressive disorder in adults. Frontiers in Immunology, 2023;14:1110775(1-8).